Novartis "R&D Day" 2003
Basel, 19. November 2003
Heute wird Novartis anlässlich ihres alljährlichen "R&D Day" in New York ihre Pharma-Pipeline den Medien und der Finanzwelt vorstellen.
Please find press conference logistics under the following link:
Recommended Reading
-
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta...
Read More -
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism...
Read More